-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Inhibikase Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2020 to Q2 2024.
- Inhibikase Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $30.7K, a 75.4% decline year-over-year.
- Inhibikase Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $336K, a 25.3% decline year-over-year.
- Inhibikase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $500K, a 9.17% increase from 2022.
- Inhibikase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $458K, a 70.1% decline from 2021.
- Inhibikase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $1.53M, a 167% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)